Biogen Inc

+0.59 (+0.18%)
4:13:44 PM EDT: $333.85 -0.70 (-0.21%)
Products, Strategic Combinations

Biogen, Innocare Announce License And Collaboration Agreement For Orelabrutinib

Published: 07/12/2021 23:10 GMT
Biogen Inc (BIIB) - Biogen and Innocare Announce License and Collaboration Agreement for Orelabrutinib, an Innovative Cns Penetrant Btk Inhibitor for the Potential Treatment of Multiple Sclerosis.
Innocare to Receive a $125 Million Upfront Payment and is Eligible to Receive Potential Development and Commercial Milestone Payments.
Biogen Will Have Exclusive Rights to Orelabrutinib in Field of Ms Worldwide and Certain Autoimmune Diseases Outside of China.
Innocare Will Retain Exclusive Worldwide Rights to Orelabrutinib in Field of Oncology and Certain Autoimmune Diseases in China.